Recognizing National Glaucoma Awareness Month

January was National Glaucoma Awareness Month and provided us an opportunity to spread the word and honor the millions of patients around the world who are impacted by this debilitating disease. ...
Read More
New Report: More than 160 medicines in development for mental illness

Mental illness represents a broad spectrum of health conditions affecting mood, thinking and behavior. These conditions include depression, bipolar disorder, schizophrenia, substance use disorder,...
Read More
ICYMI: Cancer death rate continues to decline due to treatment advances

Earlier this month, the American Cancer Society (ACS) released its annual report, Cancer Statistics 2023, finding the overall cancer mortality rate has declined 33% since peaking in 1991, leading to...
Read More
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a broad range of STEM jobs through R&D and manufacturing. At the backbone of the...
Read More
New Report: Nearly 800 medicines in development to treat chronic conditions

Chronic conditions impose a substantial health and economic burden that affects millions of patients, families and communities across the United States each day. While these conditions come with...
Read More
Recognizing National Sickle Cell Awareness Month

September is National Sickle Cell Awareness Month and a time for us to underscore the biopharmaceutical industry’s ongoing commitment to improve the lives of patients, families and communities...
Read More
Potential gene therapies bring hope to patients with sickle cell disease

A recent analysis highlights how potential gene therapies have the potential to dramatically reduce income disparities for patients with sickle cell disease, leading to as much as $21,000 more in...
Read More
Gene therapies can reduce treatment burden and costs for patients with blood disorders

A new analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for...
Read More
Report: More than 500 medicines in development to treat disorders of the blood

Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet...
Read More
Report: More than 600 medicines in development for diseases affecting women

As we approach the end of celebrating Women’s History Month, we’re taking a closer look at the biopharmaceutical progress made and challenges to be addressed for women’s health.
Read More